Reflectance Spectroscopy of Clotting Blood: A Description of the Time-Dependent Behavior

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 2, 2004, Pages 173-180

  Greco, Frank A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; ROFECOXIB;

ADULT; AGED; ANTICOAGULATION; BLOOD CLOT RETRACTION; BLOOD CLOTTING; CASE REPORT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ERYTHROCYTE; EX VIVO STUDY; FEMALE; FIBRIN POLYMERIZATION; HUMAN; INSTRUMENTATION; LIGHT INTENSITY; MALE; NORMAL HUMAN; PAIN; PHASE TRANSITION; REFLECTOMETRY; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; THROMBOSIS;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; KINETICS; MALE; MEMBRANE PROTEINS; PILOT PROJECTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SPECTRUM ANALYSIS;

EID: 0742301234     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
2. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
3. Dalen JE. Selective COX-2 inhibitors, aspirin, and myocardial infarction. Arch Intern Med. 2002;162:1091-1092.
4. Murkherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
5. Mukherjee D, Nissen SE, Topol EJ. Lack of cardioprotective effect of naproxen [letter]. Arch Intern Med. 2002;162:2637.
6. Santos MT, Valles J, Aznar J, Perez-Requejo JL. Role of red blood cells in the early stages of platelet activation by collagen. Thromb Haemost. 1986;56: 376-381.
7. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
8. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis. 2001; 12:327-337.
9. Miyashita T, Kuro M. Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg. 1998; 87:1228-1233.
10. Samra SK, Harrison RL, Bee DE, Valero V. A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann Clin Lab Sci. 1991;21:315-327.
11. Riha P, Liao F, Stolz JF. The effect of rouleaux formation on blood coagulation. Clin Hemorheol Microcirc. 1997;17:341-346.
12. Zhao H, Wang X, Stolz JF. Comparison of 3 optical methods to study erythrocyte aggregation. Clin Hemorheol Microcirc. 1999;21:297-302.
13. Dougherty G, Lowry J. Design and evaluation of an instrument to measure microcirculating blood flow and oxygen saturation simultaneously. J Med Eng Technol. 1992;16:123-128.
14. Biggs R, Macfarlane RG. Human Blood Coagulation and Its Disorders. Oxford, England: Blackwell Scientific Publications; 1957.
15. Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem. 1964;36:1627-1639.
16. Marquardt DW. An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math. 1963;2:431-441.
17. Walsh JWT. Photometry. New York, NY: Dover Publications Inc; 1958.
18. Thal LJ. Alzheimer's disease. In: Rakel RE, ed. Conn's Current Therapy. Philadelphia, Pa: WB Saunders Co; 1998:859-863.
19. Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins, VIII: the conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc. 1947;69:388-400.
20. Hantgan RR, Hermans J. Assembly of fibrin: a light scattering study. J Biol Chem. 1979;254:11272-11281.
21. Sommerfeld A. Optics. New York, NY: Academic Press; 1949.
22. Slater JC, Frank NH. Electromagnetism. New York, NY: Dover Publications Inc; 1947.
23. McMurray RW, Hardy KJ. Cox-2 inhibitors: today and tomorrow. Am J Med Sci. 2002;323:181-189.
24. Davies TA, Long HJ, Tibbles HE, et al. Moderate and advanced Alzheimer's patients exhibit platelet activation differences. Neurobiol Aging. 1997;18:155-162.
25. Greco FA, Satlin A, Solomon AK. Abnormal erythrocyte anion exchange in Alzheimer disease. Arch Pathol Lab Med. 2000;124:1141-1146.
26. Greco FA. On red cells and Alzheimer's disease. LabMedica Int. 2001;18: 16-18.
27. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. 2000;54:2066-2071.
28. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.